Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies

4Citations
Citations of this article
7Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objectives: Perioperative chemo-(radio-) therapy is the accepted standard in European patients with locally advanced adenocarcinoma of the esophagogastric junction or stomach (AEG/AS). However, 30–85% of patients do not respond to this treatment. The aim of our study was the identification of predictive biomarkers in pre-therapeutic endoscopic tumor biopsies from patients with histopathologic response (Becker-1) versus non-response (Becker-2/3) to preoperative chemotherapy. Methods: Formalin-fixed paraffin-embedded biopsies from 36 Caucasian patients (Becker-1 n = 11, Becker-2 n = 7, Becker-3 n = 18) with AEG/AS, taken prior to neoadjuvant chemotherapy were selected. For RNA expression analysis, we employed the NanoString nCounter System. To identify genomic alterations like single nucleotide variants (SNV), copy number variation (CNV) and fusion events, we used Illumina TST170 gene panel. For HER2 and FGFR2 protein expression, immunostaining was performed. Furthermore, we analyzed the microsatellite instability (MSI) and Epstein–Barr virus (EBV) infection status by EBER in situ hybridization. Results: Heat map and principal component analyses showed no clustering by means of gene expression according to regression grade. Concerning two recently proposed predictive markers, our data showed equal distribution for MSI (Becker-1: 2; Becker-2: 1; Becker-3: 3; out of 29 tested) and EBV infection was rare (1/32). We could not reveal discriminating target genes concerning SNV, but found a higher mutational burden in non-responders versus responders and fusion (in 6/14) and CNV events (in 5/14) exclusively in Becker-3. Conclusions: Although we could not identify discriminating target genes, our data suggest that molecular alterations are in general more prevalent in patients with AEG/AS belonging to the non-responding Becker group 3.

References Powered by Scopus

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

54775Citations
N/AReaders
Get full text

Use of Ranks in One-Criterion Variance Analysis

9128Citations
N/AReaders
Get full text

Graph-based genome alignment and genotyping with HISAT2 and HISAT-genotype

7217Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Neoadjuvant Chemotherapy in Asian Patients With Locally Advanced Gastric Cancer

4Citations
N/AReaders
Get full text

A multi-institutional study to evaluate the feasibility of next-generation sequencing and genomic analysis using formalin-fixed, paraffin-embedded biopsies of gastric cancer

4Citations
N/AReaders
Get full text

Application of spatial omics in gastric cancer

1Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Kleo, K., Jovanovic, V. M., Arndold, A., Lehmann, A., Lammert, H., Berg, E., … Daum, S. (2023). Response prediction in patients with gastric and esophagogastric adenocarcinoma under neoadjuvant chemotherapy using targeted gene expression analysis and next-generation sequencing in pre-therapeutic biopsies. Journal of Cancer Research and Clinical Oncology, 149(3), 1049–1061. https://doi.org/10.1007/s00432-022-03944-z

Readers over time

‘22‘23‘2501234

Readers' Seniority

Tooltip

Researcher 3

75%

PhD / Post grad / Masters / Doc 1

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

100%

Article Metrics

Tooltip
Mentions
News Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free
0